|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.
|
30098506 |
2018 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa.
|
28677795 |
2017 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Overall, our results show how CtBP2 contributes to prostate cancer progression by modulating AR and oncogenic signaling.
|
25228652 |
2014 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
|
24332637 |
2014 |
|
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
CTD_human |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
|
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
GWASDB |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.
|
28414304 |
2017 |
|
Neoplasm Invasiveness
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.
|
28414304 |
2017 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
|
Prostate carcinoma
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.
|
30098506 |
2018 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa.
|
28677795 |
2017 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
|
24332637 |
2014 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Overall, our results show how CtBP2 contributes to prostate cancer progression by modulating AR and oncogenic signaling.
|
25228652 |
2014 |
|
Prostate carcinoma
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
|
Prostate carcinoma
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A small-molecule inhibitor of CtBP2, 4-chloro-hydroxyimino phenylpyruvate (4-Cl-HIPP) phenocopied Ctbp2 deletion, decreasing tumor burden similarly to gemcitabine, and the combination of 4-Cl-HIPP and gemcitabine further synergistically suppressed tumor growth.
|
31586042 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As CtBP2 is targetable by an inhibitor of its dehydrogenase domain, understanding CtBP2's role in adenoma formation is necessary to optimize CtBP-targeted therapies in <i>Apc</i> mutated human neoplasia.
|
30197752 |
2018 |